Technical Analysis for NTLA - Intellia Therapeutics, Inc.

Grade Last Price % Change Price Change
grade F 14.415 -2.67% -0.40
NTLA closed down 6.15 percent on Wednesday, May 22, 2019, on 79 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical NTLA trend table...

Date Alert Name Type % Chg
180 Bearish Setup Bearish Swing Setup -2.67%
Fell Below 20 DMA Bearish -7.30%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -10.58%
Crossed Above 20 DMA Bullish -10.58%
NR7 Range Contraction -10.58%
NR7-2 Range Contraction -10.58%
Up 3 Days in a Row Strength -10.58%
NR7 Range Contraction -9.23%
Inside Day Range Contraction -9.23%
180 Bearish Setup Bearish Swing Setup -3.64%

Older signals for NTLA ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Intellia Therapeutics Inc., a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism; and ex vivo applications of the technology in chimeric antigen receptor T cell and hematopoietic stem cell product candidates. It has a strategic collaboration and license agreement with Novartis focused on the development of new ex vivo CRISPR/Cas9-based therapies. Intellia Therapeutics Inc. was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics Inc. in July 2014. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Medicine Biotechnology Biology Immune System Emerging Technologies Molecular Biology Genetics Inborn Errors Of Metabolism Genome Editing Antitrypsin Deficiency Chimeric Antigen Receptor Liver Diseases Cas9 CRISPR Transthyretin Amyloidosis
Is NTLA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 32.95
52 Week Low 11.03
Average Volume 534,099
200-Day Moving Average 19.0956
50-Day Moving Average 16.539
20-Day Moving Average 15.8285
10-Day Moving Average 15.585
Average True Range 0.9889
ADX 10.79
+DI 17.1795
-DI 23.6876
Chandelier Exit (Long, 3 ATRs ) 14.5733
Chandelier Exit (Short, 3 ATRs ) 17.1767
Upper Bollinger Band 17.3751
Lower Bollinger Band 14.2819
Percent B (%b) 0.17
BandWidth 19.541965
MACD Line -0.3281
MACD Signal Line -0.2579
MACD Histogram -0.0702
Fundamentals Value
Market Cap 534.82 Million
Num Shares 36.1 Million
EPS -1.33
Price-to-Earnings (P/E) Ratio -11.14
Price-to-Sales 42.05
Price-to-Book 5.07
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 16.30
Resistance 3 (R3) 16.45 16.12 16.05
Resistance 2 (R2) 16.12 15.74 16.04 15.96
Resistance 1 (R1) 15.46 15.50 15.30 15.31 15.88
Pivot Point 15.13 15.13 15.04 15.05 15.13
Support 1 (S1) 14.47 14.75 14.31 14.32 13.74
Support 2 (S2) 14.14 14.51 14.06 13.66
Support 3 (S3) 13.48 14.14 13.57
Support 4 (S4) 13.33